Clinuvel’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. Clinuvel develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.
Clinuvel Blog Posts
In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...Read More
The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...Read More
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...Read More
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...Read more